LeonaBio, Inc.
LONA
NASDAQ·Healthcare·Biotechnology·Mkt cap $29.8M
$7.56
▼ -1.82%
P/E
—
Mkt Cap
$29.8M
52-Wk Range
$4.25–$11.91
52-Week Range
$4.25 - $11.91
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 96.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary small molecule technology platform targeting neuronal health
- Clinical-stage pipeline with differentiated mechanisms of action
- Specialized expertise in neurodegenerative disease mechanisms
- Strategic focus on underserved neurological indications
Bear Case
1 risk
- High volatility (beta 2.1). Larger-than-normal price swings expected.
Growth
Stable outlook
Advancement of ATH-1105 and ATH-1020 through clinical development stages
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-12.0% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying LONA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 14, 2026
Reported EPS of -$0.80 vs -$1.39 consensus (+42.4% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+42.4%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Jul 30, 2026
vs Industry
How LONA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.